Rethinking the role of serotonin receptor signaling in improving autism symptoms: Prucalopride for a sub-group?

For many years, serotonin has been discussed in autism as though the important question were simply whether serotonin is too high or too low. I wonder whether that is asking the wrong question.

Perhaps the more useful question is: What are the individual serotonin receptors doing? And, more importantly: Is a particular receptor signalling too much or too little in a particular person?

This distinction could be important because different serotonin receptors have very different functions and signalling pathways. Some can be stimulated by agonist drugs, while others can be blocked by antagonists. Even more interestingly, the same receptor might conceivably require opposite treatment directions in different people.

A recent email from a long-time reader prompted me to look at this question much more closely.

 

A remarkable observation from a reader

One of our long-time readers wrote to me about her adult autistic son. He has suffered from severe rages for years. BCAA and Niagen had helped to some extent, and Pantogam helped significantly for a few months, but nothing had provided a lasting solution.

More recently, his gastrointestinal motility deteriorated. The mother wondered whether this physical problem might itself be contributing to his increasingly dark mood. Then something unexpected happened. The doctor gave him a few tablets of prucalopride as a trial.

The result was remarkable. His motility improved almost immediately and, at the same time, his mood became dramatically better. His mother noticed his smile returning and described him as sometimes almost giddy.

When the prucalopride ran out, they switched to Cape Aloe, a herbal laxative. That was not successful. His doctor subsequently prescribed prucalopride again, and again there was a dramatic improvement—not only in GI but also in his mood.

There are obvious limitations to a single observation. But the pattern here is a real off-drug/on-drug rechallenge, not a one-off anecdote: prucalopride on, improvement; prucalopride replaced by Cape Aloe, no improvement; prucalopride restarted, improvement again. That is a meaningfully stronger than a single before-and-after report, even though we still do not know whether the mood improvement was caused directly by prucalopride, by the relief of gastrointestinal dysfunction, or by both.

But there is something about this report that makes it particularly interesting: Prucalopride is a selective 5-HT4 receptor agonist. That means our reader may have provided us with an observation involving a very specific serotonin receptor rather than simply “serotonin.”

 

Not the first mention on this blog

Looking back through years of reader comments, this is not actually the first time prucalopride has come up here. Several readers have independently mentioned it as a helpful prokinetic going back to 2018, when a reader recommended it alongside low-dose erythromycin for a son's motility issues. In 2020, another commenter shared a paper on prucalopride's neuroprotective effects on human enteric neurons. And a reader named Leen described, across two separate updates in 2021 and 2023, resolving years of chronic fatigue, concentration problems, autonomic symptoms and mood swings using a regimen that included prucalopride—explicitly describing it as "a serotonin agonist that works in the gut."

None of these comments were prompted by a question about prucalopride specifically, and none reported the same dramatic rage improvement our most recent correspondent described. But taken together, they mean this is not really an n of 1. It is at least four independent readers, over five years, converging on the same drug and the same broad mechanism—GI motility plus a serotonin-mediated effect on mood or energy—without any of them prompting each other. That kind of unprompted convergence is exactly the sort of signal this blog exists to notice.

 

Prucalopride is now available as a much cheaper generic drug

One practical point is worth mentioning. Prucalopride was originally marketed as a very expensive branded drug, and it was the high cost that prompted the approach to me. However, generic prucalopride is now available in the United States and is dramatically cheaper than the original brand-name product.

This is particularly important because the older generation of 5-HT4 agonists had significant safety problems. They are not good alternatives to Prucalopride for its potential effects inside the brain. Prucalopride was developed as a much more selective 5-HT4 agonist, with a substantially improved safety profile compared with some of the older drugs in this class.

It means that if 5-HT4 turns out to be an interesting biological target, there is already an existing, affordable and relatively selective drug capable of activating it.

 

5-HT4: a receptor connecting the gut and brain

5-HT4 receptors are found extensively in the GI tract, where their activation promotes intestinal motility. But they are also found in the brain. 5-HT4 signalling is involved in neurotransmitter release and has been studied in relation to learning, memory, depression and other CNS functions.

Importantly, 5-HT4 is coupled to Gs (stimulatory G protein), which stimulates adenylyl cyclase and increases intracellular cAMP. The pathway can be represented simply as:

5-HT4 → Gs → adenylyl cyclase → ↑ cAMP

This immediately caught my attention because cAMP is already a recurring theme in the EpiphanyASD research. There may therefore be a connection between three things that might initially appear unrelated: 5-HT4 signalling → cAMP signalling → GI function and brain function.

Human studies have shown that prucalopride can affect brain function and cognition. While prucalopride was designed primarily for peripheral gastrointestinal motility, functional neuroimaging and cognitive studies confirm that it crosses the blood-brain barrier to exert central effects even at standard clinical doses. Existing human studies do not establish prucalopride as an antidepressant or as a treatment for autism, but they do support the idea that 5-HT4 stimulation is capable of producing functional effects in the human brain. That makes our reader’s observation biologically interesting.

 

What about the gut?

5-HT4 is a major regulator of intestinal motility. This means that the improvement could potentially be explained in several different ways:

• Hypothesis 1: The gut improved the brain. Motility had deteriorated. Chronic constipation, discomfort and visceral distress can clearly affect quality of life, sleep and mood. Prucalopride restored motility; his mood improved because he felt physically better.
• Hypothesis 2: Direct CNS effects. Prucalopride activated 5-HT4 receptors in the brain, altering cAMP signalling, neurotransmitter release, neuronal activity or other aspects of brain function. The mood improvement therefore occurred partly independently of the GI improvement.
• Hypothesis 3: Both. This may be the most likely possibility. A single receptor system could affect both sides of the gut-brain axis simultaneously (5-HT4 → intestinal motility and 5-HT4 → CNS signalling). Improving the gut could improve mood and behaviour, while direct CNS effects could potentially contribute further.

There is also an important practical point: Prucalopride is designed to stimulate intestinal motility; it is not simply a passive normalizer of bowel function. Therefore, someone with normal baseline GI function might experience excessive stimulation or loose stools, whereas a person with severe slow transit may experience restoration toward normal function. That makes the baseline phenotype critical.

 

There is already a human autism connection to HTR4

A human genomic study found lower methylation of the HTR4 promoter in children with ASD compared with controls, with the inverse relationship between methylation and age reaching significance specifically in the male ASD cases.

Association of human serotonin receptor 4 promoter methylation with autism spectrum disorder

This is not proof that autistic people have abnormal brain 5-HT4 signalling—the study used peripheral blood rather than brain tissue, was relatively small and requires replication—but it provides a direct human autism association involving the gene encoding the receptor. One caveat worth stating plainly: lower promoter methylation generally predicts higher, not lower, gene expression. Taken at face value, this study points toward more 5-HT4 signalling in ASD, not less—which does not obviously predict that an agonist like prucalopride should help. I don't think that undermines the observation; it is a good illustration of the point made later in this post, that the same receptor could plausibly need opposite treatment directions in different people, and a peripheral blood methylation signal cannot by itself tell us which direction a given individual needs.

So we now have three separate observations:

1.     autism → HTR4 epigenetic association

2.     prucalopride → selective 5-HT4 activation

3.     one autistic adult → striking improvement in motility and mood

 

A remarkable connection: Dup15q syndrome

The story becomes even more interesting when we look at specific genetic neurodevelopmental syndromes. Dup15q syndrome is strongly associated with developmental disability, autism and epilepsy. Recent experimental work in a Dup15q mouse model found gastrointestinal dysmotility and a constipation-like phenotype. The researchers tested prucalopride and found not only improvement in GI transit, but also lower fecal corticosterone (a stress marker) and longer social contact duration in the treated mice. In other words, in this model, restoring 5-HT4-driven gut motility was associated with less stress and more social behaviour—the animal-model version of exactly the gut-to-mood connection our reader described.

This does not show that prucalopride improves autism symptoms or mood in people with Dup15q, but it raises an intriguing hypothesis: Could some autistic people with significant GI dysmotility represent a particularly interesting 5-HT4-responsive phenotype? That is certainly worth investigating.

 

5-HT4 is only one serotonin receptor

This is where the story broadens. There are multiple serotonin receptors, and they do not all do the same thing. A simplified map looks like this: 

5-HT1A → Gi/o → ↓cAMP

5-HT2A → Gq → PLC/Ca²⁺/PKC signalling

5-HT4 → Gs → ↑cAMP

5-HT7 → Gs → ↑cAMP

This immediately suggests that “serotonin” is far too crude a description of the system. Two people could theoretically have completely different problems with serotonin signalling even if their overall serotonin concentrations were identical: one person might have excessive signalling through one receptor, while another might have inadequate signalling through another. This raises a possibility particularly relevant to personalized medicine: Perhaps one person needs a receptor agonist while another needs an antagonist.

 

5-HT2A keeps appearing

5-HT2A is probably the serotonin receptor that has appeared most often in discussions of autism and altered perception. There is a substantial literature concerning 5-HT2A in autism, including genetic and receptor-function studies, alongside a remarkable amount of anecdotal material from autistic adults concerning psychedelic drugs such as psilocybin, which strongly activate 5-HT2A.

The EpiphanyASD material includes readers describing unusual responses to psychedelics, including one person with Asperger's who reported an unusually weak psychedelic response and wondered whether altered receptor biology might explain it. While such observations cannot be taken as proof of altered receptor function, they help generate hypotheses.

It is also important that drugs can move receptor signalling in opposite directions. For example, atypical antipsychotics like aripiprazole and risperidone feature potent 5-HT2A antagonist/inverse agonist activity as part of their complex pharmacology. Because these drugs act on multiple systems—particularly dopamine—we cannot attribute benefits solely to 5-HT2A blockade. However, it highlights how heavily clinical practice has tilted toward blocking this receptor, rarely considering whether baseline signaling might be deficient in certain individuals.

 

5-HT7 may be even more interesting

My investigation of 5-HT7 has produced an unexpected pattern. Like 5-HT4, 5-HT7 is a Gs-coupled receptor (5-HT7 → Gs → adenylyl cyclase → ↑cAMP). There is an increasingly interesting neurodevelopmental literature surrounding this receptor. Experimental activation of 5-HT7 has produced effects on synaptic plasticity, dendritic spines, synaptic protein synthesis, long-term potentiation, and learning and memory.

This is particularly interesting because these processes are disturbed in several genetic neurodevelopmental syndromes associated with autism:

• BTBR autism model: A recent study in BTBR mice found reduced 5-HT7 expression in cortical synaptic material. Selective activation of 5-HT7 with the agonist LP-211 restored synaptic protein synthesis and normalized dendritic spine abnormalities.
• Fragile X syndrome: In Fmr1 knockout mice, 5-HT7 activation reversed abnormalities in hippocampal synaptic plasticity via adenylyl-cyclase-dependent mechanisms, improving learning and behavioural outcomes.
• Rett syndrome: Experimental work in MECP2 models suggests 5-HT7 signaling can modify downstream neuronal plasticity despite the presence of the primary genetic abnormality.
• Angelman syndrome: 5-HT7 stimulation improved synaptic protein synthesis, dendritic spine density, long-term potentiation, and cognitive deficits in an Angelman mouse model.
• Pitt-Hopkins syndrome: TCF4 deficiency alters neuronal development and synaptic function. While 5-HT7 has not yet been directly studied in Pitt-Hopkins models, it represents an ideal system to test whether TCF4 disruption alters HTR7 expression, cAMP production, or downstream PKA/CREB signaling.

These distinct genetic disorders converge on synaptic plasticity and intracellular signaling pathways where serotonin receptors act as modifiable downstream regulators.

Note: 5-HT2A and 5-HT7 each appear twice above because the same receptor can plausibly be pushed in either direction depending on the person—that duality is the whole point of this table, not a typo. The 5-HT7 antagonist row is left without a named drug because selective 5-HT7 antagonists (e.g., SB-269970) remain research compounds only, with no clinically approved option yet.

 

Beyond "High" vs. "Low" Serotonin: A Precision Framework

Measuring overall serotonin levels is far too crude. Two individuals can share identical serotonin concentrations yet have entirely different receptor expression levels, binding sensitivities, or downstream intracellular responses.

This distinction explains why conventional clinical trials often yield inconclusive results. Imagine ten autistic people given a drug that blocks a specific serotonin receptor: if five improve because they have excessive baseline signaling and five deteriorate because they have deficient signaling, the net result in the trial is zero. The intervention is labeled ineffective, missing the critical underlying signal: different biological subgroups require opposite treatment directions.

Moving toward precision pharmacology requires mapping five specific parameters rather than searching for a single "autism neurotransmitter":

• Phenotype: (e.g., severe slow-transit GI dysmotility combined with mood dysregulation)
• Candidate Target Receptor: (e.g., 5-HT4 or 5-HT7)
• Pathway Mechanism: (e.g., Gs coupling → adenylyl cyclase → ↑cAMP)
• Directional Need: (Excessive vs. deficient baseline signaling)
• Targeted Intervention: (Selective agonist vs. selective antagonist)

 

Mapping Natural Experiments

Our reader’s report is not a proven treatment for autism, but it is a powerful hypothesis-generating observation. It connects severe GI dysmotility and severe mood disturbance directly to selective 5-HT4 activation via prucalopride—a mechanism supported by human HTR4 promoter methylation studies and preclinical Dup15q models.

Many readers have shared intriguing observations involving targeted pharmaceuticals, supplements, and 5-HT2A agonists like psilocybin. When examined systematically—preserving the individual context, baseline phenotype, specific agent, dose, duration, and direction of outcome—these natural experiments can help identify potential biomarkers or clinical features that predict whether a person needs signaling at a specific receptor pushed up or pulled down.

The future of serotonin-based interventions in autism will not be about simply raising or lowering global serotonin, but about matching the right receptor signaling direction to the right person.

Note: This post was enriched using the AI copilot to apply the EpiphanyASD knowledgebase and identify relevant reader observations (some of which I had forgotten about).

https://www.epiphanyasd.com/p/ai-copilot.html

Is ARIA the Best Hope for Breakthroughs in Severe Autism?

Спасибо, Сергей (Thanks Sergei!)

 

The IACC wants America to spend much more on autism research. Then, almost out of nowhere, a new initiative starts awarding $46 million grants for autism biology at UCSF, Harvard and Yale. Who is behind it — and could ARIA represent the best hope yet for genuine treatment breakthroughs in profound autism?

 

For years, families of people with severe and profound autism have been told that science is making progress.

Researchers have discovered hundreds of autism-associated genes. They can sequence genomes, study individual brain cells, map molecular pathways, grow patient-derived brain organoids. Artificial intelligence is beginning to analyse biological systems at a scale unimaginable a few years ago.

And yet there remains a perfectly reasonable question:

Where are the breakthroughs?

Where are the treatments that substantially change the lives of people with profound intellectual disability, severe epilepsy, dangerous self-injury, non-verbal communication difficulties, and lifelong dependency?

The Interagency Autism Coordinating Committee (IACC) — a US federal advisory committee that coordinates autism research and policy across government agencies — has argued that America needs substantially greater investment in autism research. But simply spending more money isn't enough. The real question is:

What kind of research should be funded — and how should it be organised?

In the last few weeks, something remarkable has started to happen. A new initiative has announced $46 million for molecular autism research at UCSF, $46 million for a Harvard-Yale project on human brain development, and major investment in clinical trial infrastructure.

So who is behind it?

The answer is Sergey Brin

The initiative is called ARIA — Aligning Research to Impact Autism, funded through CNS Quest, a programme of the Sergey Brin Family Foundation and Catalyst4, as part of a broader effort to accelerate discoveries, treatments and care for conditions affecting the central nervous system.

That immediately brings to mind another visionary builder.

First came Jim Simons

The Simons Foundation Autism Research Initiative (SFARI) changed autism research. Jim Simons, the mathematician and founder of Renaissance Technologies, directed enormous philanthropic resources toward genetics, sequencing, molecular neuroscience, rare genetic conditions, and the large collaborative datasets that built modern autism science.

The result was an explosion of knowledge. But that knowledge also revealed a paradox: there was no single autism gene, no single autism pathway. Instead, scientists found extraordinary polygenic complexity — hundreds of genes, thousands of variants, many different routes into altered brain development.

That was itself a major discovery. But it created a daunting question:

How do you turn hundreds of distinct genetic causes into something therapeutically manageable?

SFARI built the foundation. ARIA is asking what comes next.

ARIA: aligning science towards impact

Even the name is revealing. Not simply funding more autism research, but aligning research toward impact. ARIA has organised its work into interconnected research hubs, bringing multidisciplinary teams together to identify scientific bottlenecks — with explicit emphasis on people with profound autism who need lifelong, 24/7 care, and an explicit goal of developing usable treatment options.

Science is usually fragmented. One lab studies genes, another proteins, another neurons, another runs clinical trials. Discoveries don't automatically travel between them. ARIA is trying to build the bridge:

Genes → proteins → cellular networks → brain development → biological mechanisms → therapeutic targets → interventions

If autism research is going to produce real treatments, someone has to connect the links in that chain.

UCSF and molecular convergence

The first announcement that caught my attention came from the Quantitative Biosciences Institute at UCSF, awarded $46 million under ARIA's Protein-Protein Interactions Hub.

Genes produce proteins. Proteins interact and form the networks that do the actual work inside cells. UCSF researchers recently produced what they describe as the largest molecular interaction map of autism risk genes so far — and found something potentially very important:

Hundreds of apparently different genetic mutations may converge on a surprisingly small number of shared protein complexes.

Imagine Gene A, Gene B, Gene C and Gene D each causing a distinct-looking developmental disorder. At first glance, four unrelated problems requiring four unrelated treatments. But if all four eventually disrupt the same piece of molecular machinery, the therapeutic problem changes completely. Instead of needing four bespoke interventions for tiny sub-populations, researchers might be able to target a shared biological vulnerability.

This is not a universal autism drug. Autism biology is far too complicated for that. But it reframes the question from "what does autism look like?" to "what has actually gone wrong inside the cell — and can we do something about it?"

It's a question I've been asking on this blog for over a decade, in a much smaller and unfunded way: that the most productive way to think about autism may not be gene-by-gene, but as a set of shared downstream pathways — convergent biology that a relatively small number of interventions could plausibly touch. Seeing a $46 million, UCSF-led programme built explicitly around that same convergence hypothesis is, to put it mildly, encouraging.

Harvard, Yale, and the developmental movie

Shortly after, ARIA awarded another $46 million to establish a Human Developmental Neurobiology Hub at Harvard and Yale, co-led by Paola Arlotta (Harvard), Nenad Sestan (Yale), and biomedical AI researcher Marinka Zitnik.

The ambition: understand how the human brain develops, and where that development diverges in autism — one of the hardest questions in neuroscience, because you cannot repeatedly sample a developing child's brain, and every person has a different genetic background. Developmental neuroscience has mostly consisted of snapshots.

The hub combines four interconnected projects: high-resolution mapping of brain development from before birth through adolescence; cell-by-cell gene expression mapping across developmental stages; 150 patient-derived stem-cell lines used to grow brain organoids that preserve each donor's own genetic background; and a "virtual cell model" — an AI system intended to predict how cells carrying particular genetic variants develop over time, and eventually how an intervention might alter that trajectory.

The loop is meant to run: human developmental data → organoids → AI → predictions → experiments → improved models. Traditional developmental neuroscience gives snapshots; the ambition here is something closer to a movie.

The translational catch

There is, however, a real bottleneck this framework has to overcome, and it's worth naming plainly: timing.

Brain organoids and fetal tissue maps primarily capture prenatal neurogenesis and early cell migration. But profound autism is usually recognised and diagnosed postnatally, typically between ages two and four. If the biological divergences this programme maps turn out to require intervention before birth to change, their practical value for a living child will be limited.

For this architecture to deliver breakthroughs that matter to families now, it needs to identify mechanisms that stay malleable after birth — ongoing synaptic plasticity, channelopathies, neuroinflammation, metabolic signalling in mature circuits — not just the embryonic events that set development on its initial course. That's not a reason to be cynical about the programme. It's the specific scientific test it will have to pass.

NIH, SFARI and ARIA

America now has an unusual tripartite architecture: the National Institutes of Health (NIH) — the US government's main biomedical research agency, funding basic and clinical science across virtually every disease area — providing scale and infrastructure; SFARI providing deep genetic cataloguing and cohort-building; and ARIA acting as a fast-moving, high-risk engine explicitly linking molecular discovery to therapeutic targets. Government provides stability, foundations provide specialist depth, and visionary philanthropy takes the strategic risks neither of the others can.

Which raises an uncomfortable question: why is there so little comparable activity in Europe?

Cambridge, and a structural paradox

I have nothing but respect for Cambridge — both my parents studied there, as did two of my siblings, and as a STEM university it is extraordinary, with world-class strength in genetics, molecular biology, developmental biology, neuroscience, computing and AI. Which is exactly why I find its traditional approach to autism research so frustrating.

Cambridge's Autism Research Centre has historically been associated far more with psychology, cognition, autistic traits, diagnosis and social experience than with the molecular and developmental biology ARIA is now funding. Its own position has been explicit: it says it does not seek a cure for autism itself, since autism is part of who a person is — though it does support treatment of specific symptoms and associated problems that cause distress. That distinction is real and deserves to be represented fairly. But so does the philosophical difference between describing autism and investigating whether its most severe biological consequences can be prevented or reduced.

In July 2026, Cambridge received one of the largest philanthropic gifts for autism research ever made to a British university: $34.5 million from K. Lisa Yang, $28 million of it establishing the K. Lisa Yang Centre for Autism Research, the rest supporting a new clinical centre at Cambridge Children's Hospital.

Cambridge was not the only recipient. Yang's gift established matching K. Lisa Yang Centres for Autism Research at Harvard and MIT as well — institutions that, unlike Cambridge's ARC, already have deep infrastructure in exactly the kind of molecular and developmental biology ARIA is now funding. That makes the Cambridge leg of the gift more striking, not less: the same donor, with the same stated ambition, chose to make an equivalent bet on an institution whose autism centre has historically taken a markedly less scientific approach.

Lisa Yang's philanthropy is deeply personal — she has written about her own children, one more profoundly autistic than the other, and about wanting better therapies for those most severely affected. Announcing the gift, she called for centres that would "uncover therapeutics and interventions" through "daring out-of-the-box and innovative thinking."

That sets up a genuine structural paradox: a donor explicitly asking for actionable therapeutics and biological breakthroughs, given to an institution whose autism centre has, for decades, operated within a descriptive and psychological framework that has explicitly said it isn't seeking a cure. The two positions aren't necessarily incompatible — treating distressing symptoms is not the same as denying identity — but the tension is real, and whether $34.5 million is enough to pivot a legacy institution's scientific orientation toward hard translational biology is an open question. Cambridge was chosen, by its own account, because of its Autism Research Centre and its nearly thirty-year history — so this isn't a case of a donor stumbling in unaware. The question is whether she expects, and can get, a shift.

Why not East Asia?

Every major gift also carries an opportunity cost. Western prestige institutions — Harvard, MIT, Cambridge — naturally attract this kind of philanthropy, but some of the most exciting functional genomics and developmental neuroscience infrastructure right now is in East Asia: Japan's RIKEN in developmental biology and stem-cell models; South Korea in multi-omics and rapid biotech translation; Taiwan in computational biology, medical AI and precision medicine. Building equivalent hubs there would also help correct a real problem — autism genetics has been built overwhelmingly on populations of European ancestry.

None of this is an argument that Japan, Korea or Taiwan are scientifically behind — quite the opposite, they're already producing world-class science. It's a question about whether autism philanthropy is still too automatically drawn to a familiar Western prestige hierarchy, when prestige and maximum scientific impact aren't the same thing.

There's a genuine irony worth sitting with here. Lisa Yang grew up in Singapore; her former philanthropic partner Hock Tan is from Malaysia. Two donors with direct personal ties to a region now producing some of the world's sharpest developmental biology and genomics infrastructure chose, when the moment came, to route one of the largest autism gifts in British history toward a psychology-oriented centre at a famous UK university rather than toward the scientific capability that already exists closer to their own roots. Whatever the reasoning behind it, it's a missed opportunity — and a reminder of how strong the pull of the traditional Western prestige hierarchy still is, even for donors best positioned to see past it.

Is ARIA the best hope?

It's too early to know. Autism biology is notoriously resistant to easy answers, and turning a promising convergence finding in a dish into a safe, blood-brain-barrier-crossing therapy is an enormous distance to travel. Many of these projects will fail.

But ARIA is doing something genuinely different from most autism funding announcements. It isn't cataloguing more genes, and it isn't purely descriptive psychology. It connects protein complexes and organoids to AI predictive modelling and clinical trial infrastructure — asking not just what autism looks like, but what has actually gone wrong inside the cell, and where it might still be possible to intervene.

For families living with profound autism, that shift in ambition isn't just welcome. It's long overdue.

 

Aspirin plus omega-3 for gum disease — but why might it help some ADULTS with autism? Back to resolvins and FPR2

 

 

Sometimes the most interesting autism research isn't about autism.

One of the reasons I continue to read research far outside the autism field is that biology does not respect the boundaries between medical specialties.

A discovery in Alzheimer's disease can reveal something important about autism.

A mitochondrial study can suggest a new autism hypothesis.

Research into probiotics can uncover an unexpected signalling pathway.

And sometimes you have to read about gum disease.

A new clinical trial in severe periodontitis has caught my attention because it provides an intriguing piece of human evidence for a therapeutic concept I discussed in my recent post on FPR2 and inflammation resolution.

 

Epiphany: Edging closer to targeting neuro-inflammation in autism via FPR2

There is also already some autism-specific evidence involving both omega-3 and aspirin individually.

The interesting question is what happens when they are put together.

 

A brief recap of the FPR2 idea

In my recent post, I discussed a potentially important shift in how we think about neuroinflammation in autism.

Rather than simply trying to suppress inflammation, researchers are increasingly interested in the body's own mechanisms for resolving inflammation and returning tissue to a healthy state.

One of the key players is FPR2, a receptor found on immune cells as well as microglia, astrocytes, neurons and other cells in the brain.

FPR2 can be activated by naturally occurring specialized pro-resolving mediators, including Lipoxin A4 (LXA₄) and certain resolvins.

This was particularly interesting in autism because one study found lower levels of LXA₄ in children with autism, with lower levels associated with greater autism severity in that particular study.

I also discussed a new experimental drug called MR-39, which directly activates FPR2. In autism mouse models, MR-39 reduced inflammatory signalling and was associated with improvements in synaptic proteins, dendritic spine structure and social behaviour.

The important idea was therefore not simply:

"Autism involves too much inflammation."

It was:

"Could some autistic people have difficulty switching inflammation off properly?"

If so, stimulating the body's natural resolution-and-repair system might be a more sophisticated approach than simply suppressing inflammatory pathways.

At the time, MR-39 was an experimental research compound and there was no obvious practical way to activate FPR2 safely in humans.

But there may be another way of approaching the same biological system.

And this is where an unexpected paper about gum disease becomes interesting.

 

An unexpected discovery from dentistry

The new study was a multicentre randomized clinical trial involving 109 people with advanced periodontitis.

All participants received standard mechanical treatment to remove bacterial deposits beneath the gums.

They were then randomized to receive placebo, antibiotics, omega-3 plus low-dose aspirin, or both treatments.

The antibiotic group received amoxicillin and metronidazole for two weeks.

The omega-3 group received 3 grams of omega-3 per day plus 100 mg of aspirin per day for six months.

The patients were followed for a full year.

The researchers defined treatment success as having no more than four remaining deep periodontal pockets.

In everyday language, the results mean that roughly 6 out of every 10 people receiving antibiotics improved enough to reach the study's target.

But almost exactly the same proportion of people taking omega-3 plus aspirin reached the target.

The actual figures were:

• Antibiotics: 58.6%
• Omega-3 + aspirin: 57.7%
• Antibiotics + omega-3/aspirin: 57.1%
• Placebo + mechanical treatment: 23.1%

So about 6 people in 10 reached the target with antibiotics, compared with almost 6 in 10 taking omega-3 plus aspirin, while only about 2 in 10 reached it with mechanical treatment alone.

This does not mean that omega-3 and aspirin are antibiotics.

They aren't.

What is interesting is that the two approaches produced a similar clinical outcome while acting through very different biology.

 

The body has its own inflammation-resolution system

This brings us back to the FPR2 story.

We often think of inflammation as something that should simply be switched off.

But the biology is more sophisticated than that.

Inflammation is useful.

When tissue is damaged or invaded by microbes, the immune system needs to respond. The problem arises when the inflammatory response persists after the original danger has been dealt with.

The body therefore has an active system for resolving inflammation.

Specialized pro-resolving mediators, or SPMs, help coordinate this process.

They include:

• lipoxins
• resolvins
• protectins
• maresins

These molecules do not simply suppress the immune system.

They help tell it:

"The job is done. Stop fighting and start repairing."

That distinction is important.

The goal is to allow the inflammatory response to finish properly.

 

Omega-3 is already an interesting molecule in autism

It is important to make clear that omega-3 is not a new idea in autism.

There have been numerous studies investigating EPA and DHA in people with autism or ADHD. The clinical results have been inconsistent, so omega-3 cannot currently be regarded as an established treatment for the core characteristics of autism.

Nevertheless, there are several reasons why researchers have been interested in it.

EPA and DHA have important roles in the brain and are also precursors for specialized pro-resolving mediators.

So omega-3 is potentially doing something more interesting than simply acting as a conventional "anti-inflammatory."

It provides some of the raw material from which the body's inflammation-resolution system makes its signalling molecules.

Aspirin is also not a completely new idea

Aspirin is not being introduced here as an entirely new autism treatment either.

A 2024 study investigated chronic low-dose aspirin in rats exposed prenatally to valproic acid, an established animal model used to produce autism-like behaviours.

The researchers reported that aspirin:

• improved social behaviour
• reduced repetitive grooming
• reduced anxiety-like behaviour
• increased AMPK activity in the hippocampus.

The study therefore provides an autism-specific experimental reason to be interested in aspirin, although obviously a rat study cannot establish that aspirin improves autism in humans.

AMPK is particularly interesting because it is one of the cell's major energy sensors and regulates processes involved in cellular energy metabolism, mitochondrial function, autophagy and cellular stress responses.

So aspirin already has an independent connection to autism research.

 

So what is new?  The interesting part is the combination

What interests me is the specific biological reason for combining them.

And that reason comes directly from the FPR2 hypothesis discussed in my previous post.

 

Omega-3 provides the ingredients

EPA and DHA are precursors for several specialized pro-resolving mediators.

But aspirin introduces an additional biochemical effect.

Aspirin can modify the activity of COX enzymes and redirect some lipid metabolism towards aspirin-triggered specialized pro-resolving mediators.

These include aspirin-triggered forms of resolvins.

Some of these resolution signals can activate FPR2.

This gives us a potential sequence:

 

This is why the combination is more interesting than either component considered in isolation.

The hypothesis is not simply:

"Omega-3 is anti-inflammatory, so perhaps it helps autism."

It is much more specific:

"If impaired inflammation resolution is relevant to a subset of autistic people, could omega-3 plus aspirin increase endogenous pro-resolving signalling and thereby activate pathways such as FPR2?"

That is a testable biological hypothesis.

This connects directly to my previous FPR2 post

In my previous post I discussed research reporting lower circulating Lipoxin A4 (LXA₄) in children with autism, with lower LXA₄ associated with greater autism severity in that particular study.

LXA₄ is itself a specialized pro-resolving mediator and an important FPR2 ligand.

I also discussed the experimental FPR2 agonist MR-39.

MR-39 attempts to activate the resolution system directly through FPR2.

The omega-3/aspirin approach would be different.

Rather than directly activating FPR2 with a synthetic drug, it would attempt to increase the body's own production of pro-resolving signals upstream.

So there are now two conceptually different approaches to the same biological system:

MR-39 → direct FPR2 activation

versus

omega-3 + aspirin → increased pro-resolving lipid mediator production → FPR2 and related pathways

 

The latter is obviously much less specific than a dedicated FPR2 agonist.

But biologically, the two ideas converge.

 

Why might this matter to some autistic adults?

A treatment given during early brain development is not necessarily going to have the same effect in an adult.

However, the fact that autism is developmental does not mean that all associated biological abnormalities become permanently fixed once development ends.

An autistic adult can still have differences in:

• immune signalling
• microglial activity
• mitochondrial function
• cellular energy metabolism
• synaptic plasticity
• inflammatory signalling.

If persistent neuroinflammation or metabolic stress is present in a particular person, it is conceivable that changing that biology could improve how the existing neural network functions.

It might mean improving particular domains of function.

For example:

executive function

cognitive flexibility

social engagement

repetitive behaviour

Whether this actually happens in humans remains unknown.

 

Perhaps omega-3 alone is not the whole story

There have already been numerous studies of omega-3 supplementation in autism.

The inconsistent results are interesting.

Perhaps simply supplying more EPA and DHA is not sufficient.

The important question might instead be:

Can the individual efficiently convert those fatty acids into the pro-resolving mediators needed to terminate inflammation?

If the bottleneck is downstream of the fatty acid itself, increasing omega-3 intake may have limited effects.

Aspirin could potentially change the metabolic pathway and increase formation of certain aspirin-triggered pro-resolving mediators.

The dental study provides an important human clue

This is where the periodontitis trial becomes relevant.

The researchers were not trying to treat autism.

They were trying to treat severe gum disease.

Yet omega-3 plus low-dose aspirin produced a clinical result remarkably similar to the antibiotic treatment.

That does not prove anything about autism.

Periodontal inflammation and neuroinflammation are obviously not the same thing.

But it does provide human evidence that manipulating the body's resolution pathways can produce a substantial clinical effect in a chronic inflammatory disease.

That makes the underlying concept more interesting.

And the fact that the treatment did not appear to provide additional benefit when simply added to antibiotics is also intriguing.

The omega-3/aspirin intervention was not just acting as another antibiotic.

It appears to have been addressing a different part of the disease process.

 

Who might respond?

I would not expect every autistic person to respond.

If the mechanism is correct, the likely responders might be people with some combination of:

• persistent inflammatory signalling
• altered immune regulation
• oxidative or metabolic stress
• impaired inflammation resolution
• altered lipid mediator profiles.

That immediately suggests a precision-medicine approach.

Rather than giving the treatment to everybody with an autism diagnosis, identify people whose biology suggests that this particular pathway is abnormal.

 

An important warning about aspirin

There is an obvious reason to be cautious here.

Aspirin is a drug, not a nutritional supplement.

It affects platelet function and can increase bleeding risk. It also has important age-specific safety considerations.

In particular, aspirin should not routinely be given to children or teenagers because of the risk of Reye's syndrome associated with aspirin exposure during certain viral illnesses.

The discussion here is therefore particularly relevant to the question of adult autism, and even there it remains a research hypothesis rather than a treatment recommendation.

 

Why reading outside autism matters

This is perhaps the most important lesson from this whole exercise.

The autism research gave us one piece:

reduced LXA₄ and the possibility of impaired resolution

The FPR2 research gave us another:

direct activation of an inflammation-resolution receptor can improve inflammatory and synaptic abnormalities in autism animal models.

The aspirin/autism animal study gave us another:

low-dose aspirin can alter AMPK signalling and improve autism-like behaviours in rats.

And then a group of researchers studying gum disease unexpectedly supplied another:

omega-3 plus low-dose aspirin can produce a clinical outcome comparable to antibiotics in severe periodontal disease.

But biology does not care whether a paper is published in a dental journal, an autism journal, a neuroscience journal or a mitochondrial journal.

The same molecules and signalling pathways operate across different diseases.

This is why I think anyone seriously interested in autism needs to read far beyond autism research.

Occasionally, it is in a paper about gum disease!

For the moment, I would regard omega-3 plus low-dose aspirin as an intriguing hypothesis for a subset of autistic adults, not as an established autism treatment.

But given the existing evidence for omega-3, the experimental evidence for aspirin, the FPR2/LXA₄ hypothesis, and now the unexpected human findings in periodontitis, I think it is a hypothesis worth testing if you want an OTC anti-inflammatory therapy.